過体重または肥満を伴う慢性腎臓病および2型糖尿病患者の腎障害が、セマグルチド、カグリリンチド、プラセボと比較してカグリセマによって軽減されるかどうかを調査する研究

基本情報

NCT ID

NCT06131372

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

626

治験依頼者名

Novo Nordisk A/S

概要

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, semaglutide, cagrilintide or placebo. Which treatment participant will get is decided by chance (like flipping a coin). Study doctor will not know which of the study medicines participant will get. For each participant, the study will last for about 35 weeks.

対象疾患

介入

依頼者（Sponsor）

実施施設 (8)